Skip to content
My WebMD Sign In, Sign Up

Cancer Health Center

Font Size

Childhood Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Diagnosis and Staging

Table 2. Criteria Used for the Classification of Risk Groups in Childhood Hodgkin Lymphoma Clinical Trialsa

TrialLow RiskIntermediate RiskHigh Risk
E = extralymphatic.
a Adapted from Kelly.[16]
Children's Oncology Group
AHOD0031[17] IA bulk or E; IB; IIA bulk or E; IIB; IIIA, IVA 
AHOD0431[18]IA, IIA with no bulk  
AHOD0831  IIIB, IVB
C5942[19]IA, IB, IIA with no bulk, no hilar nodes and <4 sitesIA, IB, IIA with bulk, hilar nodes or ≥4 sites; IIIIV
C59704[20]  IIB/IIIB with bulk, IV
P9425/P9426[21]IA, IIA with no bulkIB, IIA, IIIA1 with bulk; IIIA2IIB, IIIB, IV
 
German Multicenter/Euronet
GPOH-HD 95; GPOH-HD 2002;PHL-C1[3,22,23]1A/B, IIAIE A/B;IIE A; IIB; IIIAIIE B; IIIE A/B; IIIB; IV
 
Stanford/St. Jude/Dana-Farber Cancer Institute Consortium
HOD05 IB, IIIA, IA/IIA with E, ≥3 sites or bulk 
HOD08IA, IIA with no bulk, E and <3 sites  
HOD99  IIB, IIIB, IV

Although all major research groups classify patients according to clinical criteria, such as stage and presence of B symptoms, extranodal involvement, or bulky disease, comparison of outcomes across trials is further complicated because of differences in how these individual criteria are defined.

Response Assessment

Further refinement of risk classification may be performed through assessment of response after initial cycles of chemotherapy or at its completion.

Interim response assessment

The interim response to initial therapy, which may be assessed on the basis of volume reduction of disease, functional imaging status, or both, is an important prognostic variable in both early- and advanced-stage pediatric Hodgkin lymphoma.[24,25] Definitions for interim response are variable and protocol specific, but can range from volume reductions of greater than 50% to the achievement of a complete response with a volume reduction of greater than 95% by anatomic imaging or resolution of FDG-PET avidity.[3,18,21]

The rapidity of response to early therapy has been used in risk stratification to tailor therapy in an effort to augment therapy in higher-risk patients or to reduce the late effects while maintaining efficacy.

Results of selected trials using interim response to titrate therapy

  • The Pediatric Oncology Group used a response-based therapy approach consisting of dose-dense ABVE-PC (doxorubicin, bleomycin, vincristine, etoposide-prednisone, cyclophosphamide) for unfavorable advanced-stage patients in combination with 21 Gy involved-field radiation therapy (IFRT).[21] The dose-dense approach permitted reduction in chemotherapy exposure in 63% of patients who achieved a rapid early response after three ABVE-PC cycles. Five-year event-free survival (EFS) was comparable for rapid early responders (86%; treated with three cycles of ABVE-PC) and slow early responders (83%; treated with five cycles of ABVE-PC) followed by 21 Gy IFRT.
  • The Children's Cancer Group (CCG) (CCG-59704) evaluated response-adapted therapy featuring four cycles of the dose-intensive BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) regimen followed by a gender-tailored consolidation for pediatric patients with stage IIB, IIIB with bulky disease, and IV Hodgkin lymphoma.[20] For rapid early responding girls, an additional four courses of COPP/ABV (cyclophosphamide, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vinblastine) (without IFRT) was given in an effort to reduce breast cancer risk. Rapid early responding boys received two cycles of ABVD followed by IFRT. Slow early responders received four additional courses of BEACOPP and IFRT. Rapid early response (defined by resolution of B symptoms and >70% reduction in tumor volume) was achieved by 74% of patients after four BEACOPP cycles and 5-year EFS among the cohort was 94% (median follow-up, 6.3 years).
1|2|3|4|5

WebMD Public Information from the National Cancer Institute

Last Updated: February 25, 2014
This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.
Next Article:

Today on WebMD

Building a Support System
Blog
cancer fighting foods
SLIDESHOW
 
precancerous lesions slideshow
SLIDESHOW
quit smoking tips
SLIDESHOW
 
Jennifer Goodman Linn self-portrait
Blog
what is your cancer risk
HEALTH CHECK
 
colorectal cancer treatment advances
Video
breast cancer overview slideshow
SLIDESHOW
 
prostate cancer overview
SLIDESHOW
lung cancer overview slideshow
SLIDESHOW
 
ovarian cancer overview slideshow
SLIDESHOW
Actor Michael Douglas
Article